Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer

PartnershipAAV8-based Gene TherapyPositive

AI Analysis

Summary

Genezen and InterAct Therapeutics announced a partnership to advance an AAV8-based gene therapy targeting liver-dominant metastatic breast cancer. The collaboration combines Genezen's manufacturing capabilities with InterAct's platform for cancer target identification and anti-metastasis therapies.

Importance:5/10

Sentiment:

0.30

gene therapyAAVpartnershipCDMOmetastatic breast cancermanufacturing

Read the original article

Published by PR Newswire Biotech on October 5, 2026 12:00 PM

Read Original